Literature DB >> 35614852

Conserved Cdk inhibitors show unique structural responses to tyrosine phosphorylation.

Jacob B Swadling1, Tobias Warnecke2, Kyle L Morris3, Alexis R Barr4.   

Abstract

Balanced proliferation-quiescence decisions are vital during normal development and in tissue homeostasis, and their dysregulation underlies tumorigenesis. Entry into proliferative cycles is driven by Cyclin/Cyclin-dependent kinases (Cdks). Conserved Cdk inhibitors (CKIs) p21Cip1/Waf1, p27Kip1, and p57Kip2 bind to Cyclin/Cdks and inhibit Cdk activity. p27 tyrosine phosphorylation, in response to mitogenic signaling, promotes activation of CyclinD/Cdk4 and CyclinA/Cdk2. Tyrosine phosphorylation is conserved in p21 and p57, although the number of sites differs. We use molecular-dynamics simulations to compare the structural changes in Cyclin/Cdk/CKI trimers induced by single and multiple tyrosine phosphorylation in CKIs and their impact on CyclinD/Cdk4 and CyclinA/Cdk2 activity. Despite shared structural features, CKI binding induces distinct structural responses in Cyclin/Cdks and the predicted effects of CKI tyrosine phosphorylation on Cdk activity are not conserved across CKIs. Our analyses suggest how CKIs may have evolved to be sensitive to different inputs to give context-dependent control of Cdk activity.
Copyright © 2022 Biophysical Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35614852      PMCID: PMC9279356          DOI: 10.1016/j.bpj.2022.05.024

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   3.699


  56 in total

1.  AMBER force-field parameters for phosphorylated amino acids in different protonation states: phosphoserine, phosphothreonine, phosphotyrosine, and phosphohistidine.

Authors:  Nadine Homeyer; Anselm H C Horn; Harald Lanig; Heinrich Sticht
Journal:  J Mol Model       Date:  2005-10-21       Impact factor: 1.810

2.  Langevin thermostat for rigid body dynamics.

Authors:  Ruslan L Davidchack; Richard Handel; M V Tretyakov
Journal:  J Chem Phys       Date:  2009-06-21       Impact factor: 3.488

3.  Disordered p27Kip1 exhibits intrinsic structure resembling the Cdk2/cyclin A-bound conformation.

Authors:  Sivashankar G Sivakolundu; Donald Bashford; Richard W Kriwacki
Journal:  J Mol Biol       Date:  2005-09-20       Impact factor: 5.469

Review 4.  Principles of CDK regulation.

Authors:  D O Morgan
Journal:  Nature       Date:  1995-03-09       Impact factor: 49.962

5.  p27 binds cyclin-CDK complexes through a sequential mechanism involving binding-induced protein folding.

Authors:  Eilyn R Lacy; Igor Filippov; William S Lewis; Steve Otieno; Limin Xiao; Sonja Weiss; Ludger Hengst; Richard W Kriwacki
Journal:  Nat Struct Mol Biol       Date:  2004-03-14       Impact factor: 15.369

6.  Brk/Protein tyrosine kinase 6 phosphorylates p27KIP1, regulating the activity of cyclin D-cyclin-dependent kinase 4.

Authors:  Priyank Patel; Benedikt Asbach; Elina Shteyn; Cindy Gomez; Alexander Coltoff; Sadia Bhuyan; Angela L Tyner; Ralf Wagner; Stacy W Blain
Journal:  Mol Cell Biol       Date:  2015-03-02       Impact factor: 5.069

7.  p27Kip1 inhibits cyclin D-cyclin-dependent kinase 4 by two independent modes.

Authors:  Arpita Ray; Melissa K James; Stéphane Larochelle; Robert P Fisher; Stacy W Blain
Journal:  Mol Cell Biol       Date:  2008-12-15       Impact factor: 5.069

8.  JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21.

Authors:  B Colleoni; S Paternot; J M Pita; X Bisteau; K Coulonval; R J Davis; E Raspé; P P Roger
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

9.  Cip/Kip cyclin-dependent protein kinase inhibitors and the road to polyploidy.

Authors:  Zakir Ullah; Chrissie Y Lee; Melvin L Depamphilis
Journal:  Cell Div       Date:  2009-06-02       Impact factor: 5.130

10.  Mechanism of p27 Unfolding for CDK2 Reactivation.

Authors:  Soumya Lipsa Rath; Sanjib Senapati
Journal:  Sci Rep       Date:  2016-05-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.